New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
09:04 EDTHALOHalozyme resumes enrollment and dosing of patients for PEGPH20 Phase 2 trial
Halozyme Therapeutics announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol agreed to with the FDA in June. PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant human hyaluronidase under development for the systemic treatment of tumors that accumulate hyaluronan.
News For HALO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
08:34 EDTHALOHalozyme receives EU Orphan Drug designation for PEGPH20
Subscribe for More Information
December 17, 2014
09:13 EDTHALOHalozyme up nearly 5% after announcing collaboration pact with Janssen
Subscribe for More Information
09:04 EDTHALOHalozyme enters collaboration pact with Janssen for ENHANZE Technology
Subscribe for More Information
09:02 EDTHALOHalozyme enters collaboration pact with Janssen for ENHANZE Technology
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use